Frelick Jeff 4

What Happened

• Jeff Frelick, CEO of Bone Biologics Corp (BBLG), received a derivative award (option) for 16,668 shares on 2026-01-08. The Form 4 lists an acquisition price of $0.00 and total reported value of $0. The award is described as an option under the company's 2015 Equity Incentive Plan and, per the filing, vests and becomes exercisable immediately.

Key Details

• Transaction date: 2026-01-08. Form 4 filed: 2026-01-21 (filed late; transactionTimeliness = 'L').
• Reported terms: 16,668-share option grant; price listed as $0.00; total shown as $0 on the form excerpt.
• Footnotes: F1 — Grant made under the 2015 Equity Incentive Plan, exempt under Rule 16b-3; vests and is exercisable immediately unless award notice states otherwise. F2 — The option is fully vested as of the report date.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.

Context

• This is an awarded derivative (option) rather than a market buy or sale — typically part of executive compensation. The filing shows the option is immediately vested and exercisable, and the $0.00 figure is how the grant was reported on the form; the filing does not in itself indicate whether any shares were exercised or sold. The late filing reduces immediacy of disclosure; Form 4s are generally required within two business days of the transaction.